MedTrace Logo

Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP)

NCT01537250 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2018-01-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and population pharmacokinetics of oral nemonoxacin in community-acquired pneumonia (CAP) subjects.

Conditions

  • Community-acquired Pneumonia

Interventions

DRUG

Levofloxacin 500 mg placebol

oral form,,once adily,7\~10 days

DRUG

Levofloxacin 500 mg placebol

oral form,,once adily,7\~10 days

DRUG

Nemonoxacin 3 tablets

oral form,once daily,7\~10 days

Sponsors & Collaborators

  • TaiGen Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yingyuan Zhang, PhD · Huashan Hospital, Fundan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01537250 on ClinicalTrials.gov